US$ 20.66
glp-1 drug class List of Receptor Agonists for Diabetes & Weight Loss Table 1 from Glucagon-Like Peptide-1
Description
Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline

New data reveals that sales growth of semaglutide and GLP-1 therapies slowed...

This has increased interest in pharmacological treatment options

What is a GLP-1 Receptor Agonist

Ozempic alternatives in the GLP-1 family offer effective weight loss pathways

Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin